Patients with cancer | Control group | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
N | Detectability | Min | Max | Mean ± SD | N | Detectability | Min | Max | Mean ± SD | |
IFN-γ | 19 | 57.6 % | 0 | 149.39 | 18.2 ± 32.28 | 2 | 6.45 % | 0 | 21,81 | 0.77 ± 3.92 |
TNF-α | 20 | 60.6 % | 0 | 93.69 | 9.71 ± 19.06 | 5 | 15.15 % | 0 | 1.55 | 0.22 ± 0.53 |
IL-2 | 26 | 78.8 % | 0 | 93.03 | 10,71 ± 19.31 | 17 | 54.8 % | 0 | 10.66 | 1.48 ± 2.08 |
IL-4 | 13 | 39.4 % | 0 | 128.81 | 11.04 ± 26.23 | 28 | 90.3 % | 0 | 11.57 | 2.42 ± 1.94 |
IL-6 | 16 | 48.5 % | 0 | 219.16 | 16.97 ± 43.99 | 31 | 100 % | 0 | 10,29 | 3.78 ± 1.79 |
IL-10 | 27 | 81.8 % | 0 | 91.44 | 8.66 ± 15.84 | 30 | 96.8 % | 0 | 11.43 | 2.36 ± 1.99 |
IL-17 | 23 | 69.7 % | 0 | 356.21 | 33.36 ± 68.29 | 5 | 16.12 % | 0 | 1.55 | 0.60 ± 3.37 |